What do systematic reviews say?

Perioperative chemotherapy vs primary surgery

• Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach,… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1606 participants
  Moderate

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Neoadjuvant chemotherapy prior to interval surgery (NACT) leads to lower surgically‐related postoperative mortality (28 days to 6 months of… compared with surgery followed by chemotherapy (PDS) (high certainty).

• Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
  RR 0.16 [0.06, 0.46]
  5 studies · 1623 participants
  High

Intervention not reported

It is very uncertain whether the intervention changes postoperative mortality (very low certainty).

• Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery 2023 · Cochrane Headline outcomes only
  Peto OR 1.41 [0.63, 3.13]
  2 studies · 351 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes postoperative mortality (very low certainty).

• Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery 2023 · Cochrane Headline outcomes only
  Peto OR 0.39 [0.12, 1.29]
  7 studies · 1051 participants
  Very low

Intervention not reported

It is very uncertain whether the intervention changes postoperative mortality (very low certainty).

• Fibrin sealants for the prevention of postoperative pancreatic fistula following pancreatic surgery 2023 · Cochrane Headline outcomes only
  Peto OR 0.24 [0.05, 1.06]
  5 studies · 517 participants
  Very low

Duct‐to‐mucosa pancreaticojejunostomy using the modified Blumgart technique vs duct‐to‐mucosa pancreaticojejunostomy using the traditional interrupted technique

• Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 210 participants
  Very low

Duct‐to‐mucosa vs invagination pancreaticojejunostomy

It is very uncertain whether duct‐to‐mucosa changes postoperative mortality compared with invagination pancreaticojejunostomy (very low certainty).

• Duct‐to‐mucosa versus other types of pancreaticojejunostomy for the prevention of postoperative pancreatic fistula… 2022 · Cochrane Headline outcomes only
  RR 0.77 [0.39, 1.49]
  10 studies · 1472 participants
  Very low

Pancreaticojejunostomy vs pancreatogastrostomy after pancreatoduodectomy

Pancreaticojejunostomy showed no clear difference in postoperative mortality compared with pancreatogastrostomy after pancreatoduodectomy (moderate certainty).

• Pancreaticojejunostomy versus pancreaticogastrostomy reconstruction for the prevention of postoperative pancreatic… 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.53, 1.34]
  10 studies · 1629 participants
  Moderate

Tourniquet use vs no tourniquet use

• Tourniquet use for people with peripheral arterial disease undergoing major lower limb amputations 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Standard valve vs self‐adjusting CSF flow‐regulating valve

• Ventriculo‐peritoneal shunting devices for hydrocephalus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

Standard valve vs self‐adjusting CSF flow‐regulating valve

• Ventriculo‐peritoneal shunting devices for hydrocephalus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low